Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2021

View Archived Issues

HepaRegeniX initiates first-in-human trial of HRX-0215

China Pharmaceutical University targets WDR5/MLL1 interaction with DDO-2213

GentiBio closes Series A financing to advance its pipeline of engineered Treg therapies

First patient dosed in phase I study of AVA-6000

IN8bio completes dosing of first cohort in phase I study of INB-100

Janssen describes mutant FimH compositions

Positive interim analysis data from phase II/III study of plonmarlimab in severe COVID-19

Jiangsu Hengrui Medicine and collaborators patent antibacterials

New PTPN11 inhibitors discovered at Betta Pharmaceuticals

Nuvation Bio identifies new adenosine A2a receptor antagonists

SAB-185 potently neutralizes delta and lambda SARS-CoV-2 variants in nonclinical studies

Oxford Vacmedix receives approval for its first-in-human study of OVM-200 cancer vaccine

Lynk initiates dosing in phase I study of its triple-kinase inhibitor LNK-01002

RemeGen completes phase II study of telitacicept in IgAN

FDA clears IND for XeriSol levothyroxine subcutaneous injection

Imatinib preserves Beta-cell function in subjects with type 1 diabetes

Cali Biosciences initiates MERIT-1 study of long-acting ropivacaine for postoperative pain

Further data from phase I study of UV-1 in metastatic melanoma

JadiCell shows superior neurogenesis induction in model of viral-induced cognitive dysfunction

Algernon Pharmaceuticals announces SCLC research program for ifenprodil

Enrollment ongoing in phase II studies of ABBV-154

Marker of neuroaxonal injury is also a marker of worse outcomes in COVID-19 patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...